At the beginning of May, Novo Nordisk announced positive topline results from its STEP 4 study, a Phase IIIa study investigating the use of its drug semaglutide to achieve sustained weight reduction for patients suffering from obesity. STEP 4 trial is a randomised, double-blind, multicenter, placebo-controlled, withdrawal trial investigating the use of the subcutaneously administered drug versus placebo.
The result is major for the worldwide obesity market, where Novo’s drug Saxenda (liraglutide) presently occupies a 55% market share. Read more here.
Go deeper with GlobalData
